CardioRenal wins FDA IDE for RenalPro pivotal trial

CardioRenal Systems received FDA IDE approval for a pivotal study of RenalPro in cardiac surgery and added investment from St. Elizabeth Healthcare and Angel Physicians Fund. The milestones move the Milford, Massachusetts company closer to U.S. market approval for a device aimed at preventing acute kidney injury in hospitalized patients.

Why it matters: - CardioRenal Systems now has FDA clearance to start a pivotal U.S. trial of RenalPro in cardiac surgery. - The study is aimed at preventing cardiac surgery-associated acute kidney injury, a complication tied to longer ICU stays, higher costs and worse outcomes. - The new capital from a major regional health system adds clinical and strategic backing as the company pushes toward U.S. market approval.

What happened: - CardioRenal Systems received FDA Investigational Device Exemption approval for the pivotal trial of RenalPro in cardiac surgery. - The company also secured new investments from St. Elizabeth Healthcare and Angel Physicians Fund. - The IDE approval allows enrollment to begin in the pivotal study for prevention of cardiac surgery-associated acute kidney injury. - CardioRenal Systems said the milestone builds on earlier FDA Breakthrough Device Designation and European clinical evidence. - The company is headquartered in Milford, Massachusetts.

The details: - RenalPro is a clinical-stage medical device intended to prevent acute kidney injury in hospitalized patients. - The pivotal trial will study prevention of cardiac surgery-associated acute kidney injury, often shortened to CSA-AKI. - CardioRenal Systems said multiple randomized, controlled trials in Europe supported the device’s CE Mark. - The company said it is now working to begin the pivotal study at centers across the U.S. and Europe. - St. Elizabeth Healthcare serves patients in Northern Kentucky, Southeastern Indiana and Greater Cincinnati. - St. Elizabeth’s cardiac surgery program at the Florence Wormald Heart and Vascular Institute in Edgewood, Kentucky, ranks among the top 10% of programs nationwide by the Society of Thoracic Surgeons. - St. Elizabeth operates six facilities and more than 172 primary care and specialty practices. - The health system says it provides more than $100 million in uncompensated care and community benefits each year.

Between the lines: - The FDA IDE approval reduces regulatory uncertainty and lets CardioRenal test RenalPro in a pivotal U.S. study. - The investment from a hospital system with a high-profile cardiac surgery program could support clinical adoption if the data are positive. - Acute kidney injury is also a reimbursement and operational issue for hospitals, not just a clinical one, which raises the commercial stakes for any successful prevention device. - CardioRenal positioned RenalPro as a possible standard-of-care option, but that outcome depends on trial results and FDA review.

What's next: - CardioRenal Systems plans to begin the pivotal study in centers across the U.S. and Europe. - The company still needs favorable clinical results and additional regulatory progress before RenalPro can reach the U.S. market. - In the U.S., RenalPro remains investigational and has not been demonstrated to be safe or effective for marketing purposes. - Outside the U.S., the device holds a CE mark under the name RenalGuard Therapy® for balanced fluid management.

The bottom line: - CardioRenal Systems has reached a key regulatory and financing milestone, but the next phase will determine whether RenalPro can translate prior European data into U.S. approval and commercial use.

More information: CardioRenal Systems - St. Elizabeth Healthcare - CardioRenal Systems on LinkedIn